Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€68.40

€68.40

-0.870%
-0.6
-0.870%
€120.57
 
25.06.25 / Tradegate WKN: A0YD8Q / Symbol: MRK / Name: Merck & Co / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15JS chart by amCharts
Select a timeframe to show chart data
From: to:
Zoom:

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Merck & Co. Inc. is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for Merck & Co

sharewise wants to provide you with the best news and tools for Merck & Co, so we directly link to the best financial data sources.

News

Merck Stock: Dual Challenges for Pharma Giant
Merck Stock: Dual Challenges for Pharma Giant

Merck & Co., known as MSD outside North America, faces significant developments in both its pharmaceutical and animal health divisions that could impact investor sentiment. The company recently

Merck Stock: Strategic $2B Chinese Partnership Boosts Portfolio
Merck Stock: Strategic $2B Chinese Partnership Boosts Portfolio

Merck & Co. has entered a landmark licensing agreement with Chinese pharmaceutical company Jiangsu Hengrui Pharmaceuticals for HRS-5346, an oral inhibitor targeting lipoprotein(a) formation for

Merck Stock: Billion-Dollar Vaccine Facility Boosts US Presence
Merck Stock: Billion-Dollar Vaccine Facility Boosts US Presence

Merck, known internationally as MSD, has significantly strengthened its position in the American market with the opening of a new vaccine production facility in Durham, North Carolina. The